GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cessatech AS (XSAT:CESSA) » Definitions » Common Stock

Cessatech AS (XSAT:CESSA) Common Stock : kr3.49 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cessatech AS Common Stock?

Cessatech AS's quarterly common stock stayed the same from Sep. 2023 (kr2.76 Mil) to Dec. 2023 (kr2.76 Mil) but then increased from Dec. 2023 (kr2.76 Mil) to Mar. 2024 (kr3.49 Mil).

Cessatech AS's annual common stock increased from Dec. 2021 (kr1.22 Mil) to Dec. 2022 (kr2.76 Mil) but then stayed the same from Dec. 2022 (kr2.76 Mil) to Dec. 2023 (kr2.76 Mil).


Cessatech AS Common Stock Historical Data

The historical data trend for Cessatech AS's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cessatech AS Common Stock Chart

Cessatech AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Common Stock
0.74 1.22 2.76 2.76

Cessatech AS Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 2.76 2.76 2.76 3.49

Cessatech AS Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Cessatech AS (XSAT:CESSA) Business Description

Traded in Other Exchanges
Address
Kanonbadsvej 2, Copenhagen, DNK, 1437
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children.

Cessatech AS (XSAT:CESSA) Headlines

No Headlines